Avivagen Inc.
TSXV:VIV.H Rapporto sulle azioni
Cap. di mercato: CA$387.5k
Aggiungi alla lista di controlloThis company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events Avivagen Dividendi e riacquisti
Dividendo criteri di controllo 0/6 Avivagen non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
672.5%
Rendimento del riacquisto
Rendimento totale per gli azionisti 672.5% Rendimento futuro dei dividendi n/a Crescita dei dividendi n/a Prossima data di pagamento dei dividendi n/a Data di stacco del dividendo n/a Dividendo per azione n/a Rapporto di remunerazione n/a
Aggiornamenti recenti su dividendi e riacquisti
Mostra tutti gli aggiornamenti
Insufficient new directors Jul 16
Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022) Sep 30
Second quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.022 loss in 2Q 2022) Jun 07
Full year 2022 earnings: EPS and revenues exceed analyst expectations Feb 22
Avivagen Inc., Annual General Meeting, Apr 19, 2023 Feb 07
Insufficient new directors Nov 16 Avivagen Inc. announced that it expects to receive CAD 1 million in funding Oct 16
Avivagen Inc. Appoints Ira Levy as Interim CFO Sep 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Sep 16
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Jun 16
Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC) Jun 10
Avivagen Inc. Announces Oxidized Carotenoid-Based Feed Additive Product Receive Approval for Use in China May 13
Insufficient new directors Apr 27
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 01 Avivagen Inc. announced that it has received CAD 5.678 million in funding Mar 29
Avivagen Announces Approval in Vietnam Feb 24
Avivagen Inc., Annual General Meeting, Apr 08, 2022 Jan 30
Avivagen Inc., Annual General Meeting, Apr 08, 2022 Jan 29
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Jan 21
Insufficient new directors Dec 06
No longer forecast to breakeven Nov 25
Third quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.019 loss in 3Q 2020) Oct 01
No longer forecast to breakeven Jul 28
Second quarter 2021 earnings released: CA$0.041 loss per share (vs CA$0.034 loss in 2Q 2020) Jun 04
Forecast to breakeven in 2023 Jun 04
It's Unlikely That Avivagen Inc.'s (CVE:VIV) CEO Will See A Huge Pay Rise This Year Apr 02
Avivagen Inc. Announces Manuscript Reporting the Benefits of OxC-betaTM Livestock for Broiler Poultry Has Been Approved for Publication by Poultry Science Mar 05
First quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.037 loss in 1Q 2020) Mar 05
Revenue behind estimates Mar 05
Avivagen Inc. Announces the Publication of Its New Zealand OxC-beta Livestock Dairy Trial for Use Against Sub-Clinical Mastitis Feb 19
Avivagen Inc. has completed a Composite Units Offering in the amount of CAD 7.5 million. Feb 17
New 90-day high: CA$0.67 Feb 03
Mimi's Rock Corp. and Avivagen Announce Launch of Dr. Tobias Beta Blend on Amazon.Com Feb 02
Avivagen Inc., Annual General Meeting, Apr 08, 2021 Jan 30
Avivagen Inc. Announces Six Tonne Order of OxC-beta Livestock from New Customer in Mexico Jan 28
New 90-day high: CA$0.66 Jan 07
Analysts update estimates Dec 24
Revenue behind estimates Dec 17
Full year 2020 earnings released: CA$0.12 loss per share Dec 17
New 90-day high: CA$0.59 Dec 16
New 90-day high: CA$0.55 Nov 26
New 90-day low: CA$0.40 Nov 04
Avivagen Announces Record Four Tonne Order from UNAHCO Oct 14
Avivagen Inc. Receives Multiple New Orders and Joins Influential Industry Associations in Mexico Oct 07
Avivagen Inc. Receives 10 Tonne Purchase Order for OxC-Beta Livestock from Large North American Client Oct 05
New 90-day high: CA$0.51 Oct 02
Analysts update estimates Sep 09
Third quarter earnings released Sep 04
New 90-day low - CA$0.41 Aug 05
Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di VIV.H siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di VIV.H siano aumentati.
Rendimento dei dividendi rispetto al mercato Avivagen Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di VIV.H rispetto al mercato? Segmento Rendimento dei dividendi Azienda (VIV.H) n/a Fondo del 25% del mercato (CA) 1.8% Top 25% del mercato (CA) 6.1% Media del settore (Pharmaceuticals) 2.3% Analista previsionale (VIV.H) (fino a 3 anni) n/a
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di VIV.H rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di VIV.H rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di VIV.H per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché VIV.H non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}